Skip to content
Synopulse
  • The Brief
    • Quick
    • In Depth
    • Editor’s Pick
    • Findings
  • Reports
    • The beats
      • Catalyst
      • AccessWatch
      • DealPulse Signal
      • DealPulse Report
    • Analysis
      • The Throughline
      • The Top Line
      • The Forecast
    • Coverage
      • ShowFloor
      • The Arena
  • The Pulse
    • NeuroPulse
    • OrphanPulse
  • Topics
    • By subject
      • Deals
      • Regulatory
      • Market Access
      • Pricing & Reimbursement
      • Legal & Policy
    • By technology
      • Antibody
      • Cell & Gene Tx
      • Drug conjugates
      • AI/ML
      • Digital Health
      • Radiopharma
    • By therapy area
      • Neurology
      • Oncology
      • Rare Diseases
      • Cardio-Metabolic
      • Immunology & Inflammation
      • Orthopaedics
    • By Category
      • Access Read
      • CI read
      • Clinical Read
      • Deal Read
      • Science Read
New US Drugs Launched at a Median $257,000 a Year in 2025, and Only About a Third of Their Prescriptions Were Filled Within 30 Days
New US Drugs Launched at a Median $257,000 a Year in 2025, and Only About a Third of Their Prescriptions Were Filled Within 30 Days
Athithi Verma October 20, 2026

QuickAccess read/Market Access/Pricing & Reimbursement New US Drugs Launched at a Median $257,000 a Year in 2025, and Only About a Third of Their Prescriptions…

The UK Wants 92% of Dementia Referrals Diagnosed Within 18 Weeks by 2029, Up From About 60%, and Is Testing Nine Technologies to Get There
The UK Wants 92% of Dementia Referrals Diagnosed Within 18 Weeks by 2029, Up From About 60%, and Is Testing Nine Technologies to Get There
Merck KGaA Will Pay $1.3 Billion for Silence Therapeutics, Buying Its Way Into Haematology With One Phase 3-Ready siRNA
Merck KGaA Will Pay $1.3 Billion for Silence Therapeutics, Buying Its Way Into Haematology With One Phase 3-Ready siRNA
Lilly Signed Up to $1.1 Billion With METiS TechBio for AI-Designed Lipid Nanoparticles While Paying Only Low Double-Digit Millions Upfront
Lilly Signed Up to $1.1 Billion With METiS TechBio for AI-Designed Lipid Nanoparticles While Paying Only Low Double-Digit Millions Upfront
OrphanPulse Wk 42: Europe Backed Ascendis' Weekly Achondroplasia Shot Ahead of the First Pill
OrphanPulse Wk 42: Europe Backed Ascendis’ Weekly Achondroplasia Shot Ahead of the First Pill
The First US Tinnitus Guideline Update Since 2014 Names Bimodal Neuromodulation, Handing Neuromod's Lenire a Coverage Argument
The First US Tinnitus Guideline Update Since 2014 Names Bimodal Neuromodulation, Handing Neuromod’s Lenire a Coverage Argument

Editor’s Pick

Australia Set a Price Lilly Refused, So Lilly Built a Channel Around the PBS

Australia Set a Price Lilly Refused, So Lilly Built a Channel Around the PBS

Rare Disease Produced Two First-Ever Approvals in Two Days, and Both of Them Are Neurology

Rare Disease Produced Two First-Ever Approvals in Two Days, and Both of Them Are Neurology

In Ustekinumab Biosimilars, Approval Stopped Being the Hard Part

In Ustekinumab Biosimilars, Approval Stopped Being the Hard Part

NeuroPulse


NeuroPulse Wk 42: Arrowhead Cut Tau by 73% With a Shot Under the Skin

NeuroPulse Wk 42: Arrowhead Cut Tau by 73% With a Shot Under the Skin

NeuroPulse Wk 41: Teva Took the Three-Hour Wait Out of Long-Acting Olanzapine

NeuroPulse Wk 41: Teva Took the Three-Hour Wait Out of Long-Acting Olanzapine

OrphanPulse


OrphanPulse Wk 42: Europe Backed Ascendis' Weekly Achondroplasia Shot Ahead of the First Pill

OrphanPulse Wk 42: Europe Backed Ascendis’ Weekly Achondroplasia Shot Ahead of the First Pill

OrphanPulse Wk 41: BridgeBio Won Priority Review for the First Oral Achondroplasia Drug

OrphanPulse Wk 41: BridgeBio Won Priority Review for the First Oral Achondroplasia Drug

DealPulse Signal


DealPulse Signal Wk 42: STERIS Paid $2.1 Billion for Surgical Consumables, and No Drug Made the Top Five

DealPulse Signal Wk 42: STERIS Paid $2.1 Billion for Surgical Consumables, and No Drug Made the Top Five

DealPulse Signal Wk 41: McKesson Bought Into Home Infusion and Shionogi Bought the Next Label

DealPulse Signal Wk 41: McKesson Bought Into Home Infusion and Shionogi Bought the Next Label

DealPulse Report


DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealFlow H1 2026 M&A Doubles as Upfront Spending Hits $174B

DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B

The Beats


DealPulse Signal Wk 42: STERIS Paid $2.1 Billion for Surgical Consumables, and No Drug Made the Top Five

DealPulse Signal Wk 42: STERIS Paid $2.1 Billion for Surgical Consumables, and No Drug Made the Top Five

DealPulse Signal Wk 41: McKesson Bought Into Home Infusion and Shionogi Bought the Next Label

DealPulse Signal Wk 41: McKesson Bought Into Home Infusion and Shionogi Bought the Next Label

DealPulse Signal Wk 39: Telix Paid in Stock and the Platforms Paid in Promises

DealPulse Signal Wk 39: Telix Paid in Stock and the Platforms Paid in Promises

Analysis


Radiopharmaceuticals: sixteen years of deal data on where the field goes next

Radiopharmaceuticals: sixteen years of deal data on where the field goes next

Behind the Headlines How the Leaders Really Performed

Behind the Headlines: How the Leaders Really Performed

Reshaping Pharma by 2027

7 Market Access Trends Reshaping Pharmaย by 2027

Coverage


ESMO 2026 Preview: Seven of Twelve Presidential Abstracts Have Already Claimed a Survival Win

ESMO 2026 Preview: Seven of Twelve Presidential Abstracts Have Already Claimed a Survival Win

ADCs Returned 0.46 in Relapsed Disease and 1.15 in the Front Line at WCLC

The ADC Decade Accelerates What to Watch at ASCO 2026

The ADC Decade Accelerates: What to Watch at ASCO 2026

The Briefs

New US Drugs Launched at a Median $257,000 a Year in 2025, and Only About a Third of Their Prescriptions Were Filled Within 30 Days

New US Drugs Launched at a Median $257,000 a Year in 2025, and Only About a Third of Their Prescriptions Were Filled Within 30 Days

Athithi Verma October 20, 2026
The UK Wants 92% of Dementia Referrals Diagnosed Within 18 Weeks by 2029, Up From About 60%, and Is Testing Nine Technologies to Get There

The UK Wants 92% of Dementia Referrals Diagnosed Within 18 Weeks by 2029, Up From About 60%, and Is Testing Nine Technologies to Get There

Athithi Verma October 20, 2026
Merck KGaA Will Pay $1.3 Billion for Silence Therapeutics, Buying Its Way Into Haematology With One Phase 3-Ready siRNA

Merck KGaA Will Pay $1.3 Billion for Silence Therapeutics, Buying Its Way Into Haematology With One Phase 3-Ready siRNA

Athithi Verma October 20, 2026
Lilly Signed Up to $1.1 Billion With METiS TechBio for AI-Designed Lipid Nanoparticles While Paying Only Low Double-Digit Millions Upfront

Lilly Signed Up to $1.1 Billion With METiS TechBio for AI-Designed Lipid Nanoparticles While Paying Only Low Double-Digit Millions Upfront

Athithi Verma October 20, 2026
The First US Tinnitus Guideline Update Since 2014 Names Bimodal Neuromodulation, Handing Neuromod's Lenire a Coverage Argument

The First US Tinnitus Guideline Update Since 2014 Names Bimodal Neuromodulation, Handing Neuromod’s Lenire a Coverage Argument

Athithi Verma October 19, 2026
AbbVie's Skyrizi Combination Nearly Doubled Endoscopic Remission at 24 Weeks in Crohn's, in an Open-Label Study Without Placebo

AbbVie’s Skyrizi Combination Nearly Doubled Endoscopic Remission at 24 Weeks in Crohn’s, in an Open-Label Study Without Placebo

Athithi Verma October 19, 2026
Read More
Synopulse
Contact Us

Explore Synopulse

  • NeuroPulse
  • Deals
  • Market Access
  • Industry Trends
  • Regulatory

About

  • About Synopulse
  • Contact Us
  • Announcements
© 2026 Synopulse • Built with GeneratePress